Cholesterol is one of the most commonly measured markers in medicine — and one of the most misunderstood. Patients are often told their cholesterol is "a bit high" without being given a clear explanation of what that means, which number is the problem, or what the clinical implications are. According to the Health Survey for England 2021, 59% of UK adults have raised total cholesterol — defined as above 5.0 mmol/L — yet the majority have no symptoms and are unaware of their cardiovascular risk[1].
Understanding your cholesterol numbers is not simply a matter of knowing whether a figure is above or below a threshold. It requires understanding the relationship between different lipid fractions, your overall cardiovascular risk profile, and the evidence-based targets that apply to your individual situation. This guide explains each number, what the current NICE guidance recommends, and when to seek further assessment from a private GP or cardiologist.
1. What Is Cholesterol and Why Does It Matter?
Cholesterol is a waxy, fat-like substance produced by the liver and obtained from dietary sources. It is essential for the production of cell membranes, steroid hormones, bile acids, and vitamin D. The body regulates cholesterol production carefully — when dietary intake is high, hepatic synthesis decreases, and vice versa. However, in a significant proportion of the population, this regulatory mechanism is insufficient to maintain optimal levels, particularly in the presence of genetic predisposition, dietary excess, or metabolic disease.
Cholesterol is transported in the bloodstream by lipoproteins — protein-lipid complexes that vary in density and function. The clinically important fractions are low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL, which carries triglycerides). Each fraction has a distinct relationship with cardiovascular risk, and understanding the difference between them is essential for interpreting a lipid panel result.
The relationship between elevated LDL cholesterol and atherosclerotic cardiovascular disease (ASCVD) — the process by which cholesterol-rich plaques accumulate in arterial walls, causing coronary artery disease, stroke, and peripheral arterial disease — is one of the most robustly established causal relationships in medicine[4]. Reducing LDL cholesterol reduces cardiovascular events in a dose-dependent manner, regardless of baseline risk.
2. Understanding Your Cholesterol Numbers
A standard lipid panel measures four values: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Some laboratories also calculate non-HDL cholesterol (total cholesterol minus HDL), which NICE NG238 now recommends as the primary treatment target because it captures all atherogenic lipoproteins, including VLDL and lipoprotein(a)[2].
| Lipid Fraction | What It Measures | Optimal Level | Cardiovascular Effect |
|---|---|---|---|
| Total Cholesterol | All cholesterol fractions combined | < 5.0 mmol/L | Elevated total cholesterol increases ASCVD risk |
| LDL Cholesterol | Low-density lipoprotein — the primary atherogenic fraction | < 3.0 mmol/L (primary prevention) | Directly causal in atherosclerosis — the main treatment target |
| HDL Cholesterol | High-density lipoprotein — 'protective' cholesterol | > 1.0 mmol/L (men) / > 1.2 mmol/L (women) | Higher HDL is associated with lower cardiovascular risk |
| Non-HDL Cholesterol | Total cholesterol minus HDL — captures all atherogenic lipoproteins | < 3.4 mmol/L (primary prevention) | NICE NG238 primary treatment target — more predictive than LDL alone |
| Triglycerides | Fats transported by VLDL — reflects dietary fat and metabolic health | < 1.7 mmol/L (fasting) | Elevated triglycerides independently increase cardiovascular risk |
| Total:HDL Ratio | Total cholesterol divided by HDL | < 4.0 | Used in cardiovascular risk calculators; lower is better |
3. NICE Cholesterol Targets: Primary vs Secondary Prevention
NICE Guideline NG238 (December 2023) distinguishes between primary prevention — reducing the risk of a first cardiovascular event in people without established cardiovascular disease — and secondary prevention — reducing the risk of a further event in people who have already had a heart attack, stroke, or are diagnosed with coronary artery disease[2].
The targets differ significantly between these two groups. For secondary prevention, the evidence supports more aggressive lipid lowering — the NICE target is LDL cholesterol ≤ 2.0 mmol/L or non-HDL cholesterol ≤ 2.6 mmol/L. For primary prevention, the approach is risk-based: a 10-year QRISK3 score is calculated, and statin therapy is recommended if the 10-year cardiovascular risk exceeds 10%, with a treatment goal of ≥40% reduction in non-HDL cholesterol[3].
| Prevention Type | Who It Applies To | LDL Target | Non-HDL Target |
|---|---|---|---|
| Primary prevention | No prior CVD; 10-year QRISK3 ≥ 10% | ≥40% reduction from baseline | ≤ 3.4 mmol/L (or ≥40% reduction) |
| Secondary prevention | Established CVD (MI, stroke, angina, PAD) | ≤ 2.0 mmol/L | ≤ 2.6 mmol/L |
| Familial hypercholesterolaemia | Genetic LDL elevation (1 in 250 in UK) | ≥50% reduction from untreated baseline | Specialist-guided; often requires PCSK9 inhibitor |
| Type 2 diabetes with CVD risk | Diabetes + age ≥40 or established CVD | ≤ 2.0 mmol/L (secondary prevention applies) | ≤ 2.6 mmol/L |
4. What Causes High Cholesterol?
High cholesterol (hypercholesterolaemia) has both modifiable and non-modifiable causes. Understanding which factors are driving elevated levels in an individual patient is essential for selecting the most appropriate management strategy — lifestyle modification alone, pharmacological therapy, or a combination of both.
| Category | Cause | Modifiable? |
|---|---|---|
| Genetic | Familial hypercholesterolaemia (FH) — 1 in 250 in UK; LDL receptor mutations | No — requires pharmacological treatment |
| Genetic | Polygenic hypercholesterolaemia — multiple common gene variants | Partially — responds to diet and statins |
| Dietary | High saturated fat intake (red meat, full-fat dairy, processed foods) | Yes — dietary modification reduces LDL by 10–20% |
| Metabolic | Type 2 diabetes and insulin resistance — raises triglycerides, lowers HDL | Partially — improved with glycaemic control and weight loss |
| Thyroid | Hypothyroidism — reduces LDL receptor expression, raising LDL | Yes — treated with levothyroxine |
| Renal | Chronic kidney disease — raises LDL and triglycerides | Partially — managed with statins and renal treatment |
| Hepatic | Non-alcoholic fatty liver disease — raises LDL and triglycerides | Yes — responds to weight loss and dietary change |
| Lifestyle | Physical inactivity — lowers HDL, raises triglycerides | Yes — aerobic exercise raises HDL by 5–10% |
| Medications | Corticosteroids, thiazide diuretics, some antipsychotics | Partially — medication review may be appropriate |
| Age and sex | LDL rises with age; post-menopausal women have higher LDL than pre-menopausal | No — managed pharmacologically if risk warrants |
Familial hypercholesterolaemia (FH) deserves particular attention. It affects approximately 1 in 250 people in the UK — meaning around 270,000 individuals — but fewer than 8% are currently identified and treated[5]. FH causes markedly elevated LDL from birth and significantly increases the risk of premature coronary artery disease. If your total cholesterol is above 7.5 mmol/L, or if you have a family history of premature cardiovascular disease (before age 55 in men, 65 in women), FH should be considered and a fasting lipid panel with genetic assessment arranged.
5. Symptoms of High Cholesterol — and Why Most People Have None
High cholesterol is almost entirely asymptomatic. There are no pain receptors in arterial walls, and the gradual accumulation of atherosclerotic plaque does not cause symptoms until it reaches a critical threshold — typically when it causes significant narrowing of a coronary artery (angina), ruptures to cause a heart attack, or embolises to cause a stroke. By the time symptoms appear, significant cardiovascular disease is already established.
The only physical signs of high cholesterol are rare and typically associated with severe or familial hypercholesterolaemia: xanthelasma (yellowish plaques around the eyelids), tendon xanthomata (cholesterol deposits in tendons, particularly the Achilles), and corneal arcus (a white or grey ring around the iris, significant in people under 45). These signs are absent in the vast majority of people with elevated cholesterol, which is why routine screening through a blood test is the only reliable way to identify the condition.
Symptoms that require urgent assessment
High cholesterol itself does not cause acute symptoms. However, the cardiovascular events it causes — heart attack and stroke — are medical emergencies. Call 999 immediately if you experience:
- Severe chest pain, pressure, or tightness — especially radiating to the arm, jaw, or back
- Sudden weakness or numbness on one side of the face, arm, or leg
- Sudden difficulty speaking, understanding speech, or confusion
- Sudden severe headache with no known cause
- Sudden loss of vision in one or both eyes
6. What Tests Are Used to Assess Cholesterol and Cardiovascular Risk?
Cholesterol assessment begins with a lipid panel blood test. Current NICE guidance and ACC/AHA guidelines confirm that non-fasting lipid levels can be used for initial cardiovascular risk assessment — fasting is no longer routinely required for a first test, though it may be requested if triglycerides are elevated or if the result is being used to calculate a precise LDL level[6]. At Victoria Medical, a full lipid panel is available as a same-day blood test with results within 24 hours.
| Investigation | What It Assesses | When Ordered |
|---|---|---|
| Fasting lipid panel | Total cholesterol, LDL, HDL, triglycerides, non-HDL | First-line cholesterol assessment; baseline before treatment |
| QRISK3 calculation | 10-year cardiovascular risk score using age, sex, BP, cholesterol, diabetes, smoking, family history | Guides statin therapy decision in primary prevention |
| Thyroid function (TSH, T4) | Hypothyroidism as secondary cause of raised cholesterol | Ordered if cholesterol is unexpectedly high or resistant to treatment |
| HbA1c and fasting glucose | Type 2 diabetes or pre-diabetes as contributing factor | Ordered alongside lipid panel in patients with metabolic risk factors |
| Liver function tests | Baseline before starting statins; NAFLD as contributing cause | Required before initiating statin therapy |
| Lipoprotein(a) | Genetic cardiovascular risk marker — independent of LDL | Ordered in patients with FH, premature CVD, or statin-resistant high LDL |
| Echocardiogram | Cardiac structure and function in high-risk patients | Ordered by cardiologist if cardiac symptoms or high QRISK3 score |
| ECG | Baseline cardiac electrical activity; ischaemic changes | Ordered by GP or cardiologist in patients with cardiac symptoms |
7. When to See a GP or Cardiologist About Your Cholesterol
Not every elevated cholesterol result requires an urgent specialist appointment. The appropriate response depends on the level of elevation, the presence of other cardiovascular risk factors, and whether you have established cardiovascular disease. The following framework helps clarify when each level of care is appropriate.
See a GP when:
- Total cholesterol is above 5.0 mmol/L and you have not had a recent cardiovascular risk assessment
- LDL cholesterol is above 3.0 mmol/L (primary prevention) or above 2.0 mmol/L (secondary prevention)
- You have a family history of premature cardiovascular disease or familial hypercholesterolaemia
- You have type 2 diabetes, hypertension, or are a smoker — all of which amplify cholesterol risk
- You are already on a statin and your cholesterol is not reaching target
- You want a QRISK3 cardiovascular risk assessment and a personalised management plan
See a cardiologist when:
- Total cholesterol is above 7.5 mmol/L — possible familial hypercholesterolaemia requiring specialist management
- You have established cardiovascular disease (heart attack, angina, stroke, PAD) and are not at LDL target
- You have cardiac symptoms — chest pain, palpitations, breathlessness — alongside high cholesterol
- Your GP has started statin therapy but cholesterol remains above target after 3 months
- You need a PCSK9 inhibitor or other specialist lipid-lowering therapy
- You have a high QRISK3 score (≥20%) and want a comprehensive cardiac risk assessment including ECG and echocardiogram
From Our Practice
"The patients who concern me most are not the ones with a total cholesterol of 6.2 mmol/L who come in anxious about their result. Those patients are engaged, they are asking the right questions, and they are in the right place. The patients who concern me are the ones I see after their first heart attack at 52, who tell me they had a cholesterol result of 7.8 mmol/L five years ago and nobody followed it up. In cardiology, the window between 'elevated cholesterol' and 'established cardiovascular disease' is measured in years — and it is entirely preventable if you act in that window. A fasting lipid panel and a QRISK3 score take 30 minutes. A heart attack takes a lifetime."
Dr George Xynopoulos
MD, MRCP, FACC — Consultant Physician & Cardiologist, Victoria Medical
Frequently Asked Questions
What is a normal cholesterol level in the UK?
NICE guidance recommends a total cholesterol below 5.0 mmol/L for adults without cardiovascular disease. LDL cholesterol should be below 3.0 mmol/L for primary prevention. However, 'normal' is context-dependent — a total cholesterol of 5.2 mmol/L in a 35-year-old non-smoker without diabetes carries a very different risk profile to the same result in a 60-year-old with hypertension and a family history of heart disease. A QRISK3 cardiovascular risk assessment, available at a private GP consultation, provides a personalised risk estimate.
Do I need to fast before a cholesterol blood test?
Not always. NICE NG238 and current ACC/AHA guidelines confirm that non-fasting lipid levels can be used for initial cardiovascular risk assessment. However, a fasting sample (9–12 hours without food) is recommended if triglycerides are elevated, if you are being assessed for familial hypercholesterolaemia, or if the result will be used to calculate a precise LDL level using the Friedewald equation. At Victoria Medical, we advise on fasting requirements when you book your blood test.
Can high cholesterol be treated without statins?
Yes, in some cases. Dietary modification — reducing saturated fat, increasing soluble fibre, and adding plant sterols — can reduce LDL cholesterol by 10–20%. Regular aerobic exercise raises HDL by 5–10%. Weight loss reduces triglycerides and LDL. However, for patients with familial hypercholesterolaemia, established cardiovascular disease, or a QRISK3 score above 10%, lifestyle modification alone is usually insufficient and statin therapy is recommended by NICE. The decision should be made with your GP based on your full risk profile.
What is the difference between LDL and HDL cholesterol?
LDL (low-density lipoprotein) carries cholesterol from the liver to the body's tissues. When LDL levels are elevated, excess cholesterol deposits in arterial walls, forming atherosclerotic plaques that increase the risk of heart attack and stroke. HDL (high-density lipoprotein) carries cholesterol from the tissues back to the liver for excretion — a process called reverse cholesterol transport. Higher HDL levels are associated with lower cardiovascular risk. The key clinical target is reducing LDL and non-HDL cholesterol, while maintaining or raising HDL.
How quickly can I get a cholesterol blood test in London?
At Victoria Medical, a full fasting or non-fasting lipid panel can be arranged on the same day as your GP consultation, or as a standalone blood test without a referral. Results are available within 24 hours. The clinic is at 170 Vauxhall Bridge Road, Victoria SW1, two minutes from Victoria Station.
What is familial hypercholesterolaemia and how is it diagnosed?
Familial hypercholesterolaemia (FH) is a genetic condition caused by mutations in the LDL receptor gene, resulting in markedly elevated LDL cholesterol from birth. It affects approximately 1 in 250 people in the UK. FH is diagnosed using the Simon Broome or Dutch Lipid Clinic Network criteria, which combine lipid levels, family history, and physical signs (tendon xanthomata, corneal arcus). Genetic testing can confirm the diagnosis. FH requires specialist management — lifestyle modification alone is insufficient, and high-intensity statin therapy or PCSK9 inhibitors are typically required.
Related Guides
High Blood Pressure: Symptoms, Causes, and When to See a Doctor
Hypertension and high cholesterol frequently co-exist and amplify each other's cardiovascular risk. Dr Xynopoulos explains the NICE classification, causes, and when to see a cardiologist.
Heart Palpitations: Causes, When to Worry, and What Tests You Need
Palpitations can be a symptom of the cardiovascular complications of untreated hypercholesterolaemia. This guide explains causes, red flags, and which tests provide answers.
Private Blood Tests in London
A full lipid panel, HbA1c, thyroid function, and cardiovascular risk markers — all available same-day at Victoria Medical with results within 24 hours.
Private GP vs NHS GP: What Are the Key Differences?
Understanding the difference between NHS and private GP care — including how cholesterol and cardiovascular risk are managed in each system.
References
- [1] NHS Digital. Health Survey for England 2021: Adult Health — Cholesterol. NHS England. 2023. https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2021-part-2/adult-health-cholesterol
- [2] National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Guideline NG238. December 2023. https://www.nice.org.uk/guidance/ng238
- [3] Williams E, Sheringham J, et al. Cardiovascular disease risk assessment and reduction: NICE 2023 update for GPs. Br J Gen Pract. 2024;74(748):523–525. https://bjgp.org/content/74/748/523
- [4] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596–e646. https://www.ahajournals.org/doi/10.1161/cir.0000000000000678
- [5] Durand A, Sheringham J, et al. Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study. BMC Cardiovasc Disord. 2024;24(1):95. https://pmc.ncbi.nlm.nih.gov/articles/PMC10877619/
- [6] Allan GM, Garrison S, McCormack J. Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care. Can Fam Physician. 2015;61(10):857–867. https://pmc.ncbi.nlm.nih.gov/articles/PMC4607330/
Dr George Xynopoulos
MD, MRCP, FACC — Consultant Physician & Cardiologist
Dr Xynopoulos is a Consultant Physician and Cardiologist at Victoria Medical, 170 Vauxhall Bridge Road, London SW1V 1DX. He provides cardiovascular risk assessment, lipid management, and specialist cardiology services including ECG, echocardiogram, and cardiac risk evaluation. He holds MD, MRCP, and FACC credentials and is fully registered with the General Medical Council.
View full profile →Know Your Cholesterol Numbers Today
Same-day fasting lipid panel, QRISK3 cardiovascular risk assessment, and GP consultation — all at 170 Vauxhall Bridge Road, Victoria SW1. Results within 24 hours.